aztreonam has been researched along with vancomycin in 64 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.69) | 18.7374 |
| 1990's | 16 (25.00) | 18.2507 |
| 2000's | 16 (25.00) | 29.6817 |
| 2010's | 25 (39.06) | 24.3611 |
| 2020's | 4 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hanberger, H | 1 |
| Casewell, MW; Fagan, E; Philpott-Howard, J; Rolando, N; Wade, JJ; Williams, R | 1 |
| Langdale, V; Levene, M; MacKay, P; Martin, C; Millar, MR | 1 |
| George, WJ; Hellstrom, WJ; Neal, DE; Rege, AB; Ricci, MJ; Walters, FP | 1 |
| Kelsey, SM; Newland, AC; Shaw, E | 1 |
| Chan, CY; Cheng, IK; Wong, WT | 1 |
| Chandler, SW; Folstad, J; Trissel, LA | 1 |
| Altmann, P; Brown, J; Cunningham, J; Marsh, F; Shaw, E | 1 |
| Abe, T; Fujii, R; Hashira, S; Meguro, H; Tajima, T | 1 |
| Braveny, I; Machka, K; Milatovic, D | 1 |
| Baltch, AL; Bassey, C; Fanciullo, G; Smith, RP | 1 |
| Rouan, MC | 1 |
| Boucher, BA; Croce, MA; Fabian, TC; McKindley, DS; Proctor, KG | 1 |
| Daenen, SM; de Vries-Hospers, HG; Erjavec, Z; Halie, MR; van der Waaij, D; van Kamp, H | 1 |
| Adler, C; Hauben, M | 1 |
| Freifeld, AG | 1 |
| Martinez, JF; Trissel, LA; Xu, QA | 1 |
| Abi-Said, D; Bodey, GP; Ghaddar, HM; Hachem, RY; Karl, CL; Pandya, RG; Raad, II; Rolston, KV; Whimbey, EE | 1 |
| Cheadle, WG; Fabian, T; Fry, DE; Gardner, SA; Kesterson, L; Livingston, DH; Malangoni, MA; Polk, HC; Trachtenberg, LS | 1 |
| Cammarata, S; Oliphant, T; Rubinstein, E; Wunderink, R | 1 |
| Brade, V; Hunfeld, KP; Kekoukh, E; Kraiczy, P; Weigand, J; Wichelhaus, TA | 1 |
| Beilman, GJ; Feltis, BA; Lee, DA | 1 |
| Cammarata, SK; Kollef, MH; Oliphant, TH; Wunderink, RG | 1 |
| Thomas, GD | 1 |
| Babinchak, T; Dartois, N; Ellis-Grosse, EJ; Loh, E; Rose, G | 1 |
| Campos, ME; Curcio, D; Ellis-Grosse, E; Embil, JM; Loh, E; Penn, RL; Rose, G; Sacchidanand, S | 1 |
| Breedt, J; Dartois, N; Ellis-Grosse, EJ; Gardovskis, J; Gioud-Paquet, M; Loh, E; Maritz, FJ; Ross, DP; Teras, J; Vaasna, T | 1 |
| Itani, KM; Liu, LZ; McKinnon, PS; Sorensen, SV | 1 |
| Chang, YH; Chen, SH; Hsieh, PH; Shih, CH; Ueng, SW | 1 |
| Arakawa, S; Deguchi, T; Egashira, T; Fujime, M; Fujita, K; Fukuhara, Y; Furuya, N; Hirakata, Y; Hirose, T; Igari, J; Imafuku, Y; Ishibashi, K; Ishihara, S; Kamidono, S; Kitamura, M; Kobayashi, Y; Kohno, S; Kondo, A; Konishi, T; Kumamoto, Y; Kumon, H; Kunishima, Y; Matsuda, J; Matsuda, S; Matsukawa, M; Matsumoto, T; Monden, K; Murai, M; Muratani, T; Naito, S; Nakano, M; Oguri, T; Oka, T; Ooe, H; Sato, S; Shigeta, S; Suzutani, T; Tsukamoto, T; Uchida, H; Watanabe, K; Yamaguchi, K; Yamaguti, O; Yoshida, H | 1 |
| Das, A; Ge, Y; Talbot, GH; Thye, D | 1 |
| Cooper, A; Dartois, N; Dukart, G; Gardovskis, J; Jouve, S; Kupcs, U; Pupelis, G; Teras, J; Vaasna, T | 1 |
| LaPlante, KL; Sakoulas, G | 1 |
| Baculik, T; Corey, GR; Critchley, I; Das, AF; Friedland, HD; Talbot, GH; Thye, D; Wilcox, M; Witherell, GW | 1 |
| Baculik, T; Corey, GR; Friedland, D; Talbot, GH; Thye, D; Wilcox, MH | 2 |
| Corrado, ML | 1 |
| Aradhya, S; Chang, CM; Chuang, YC; Cooper, A; Dartois, N; Jouve, S; Nagari, B; Pai, V | 1 |
| Drusano, GL | 1 |
| Biek, D; Eckburg, PB; Friedland, HD; Laudano, JB; Llorens, L; O'Neal, T; Rank, DR; Smith, A; Thye, D; Witherell, GW | 1 |
| Ahn, SH; Biek, D; Critchley, I; Fowler, VG; Lamlertthon, S; Llorens, L; Rude, T; Ruffin, F; Sharma-Kuinkel, BK; Tamarana, G; Tong, A; Tong, SY; Zhang, Y | 1 |
| Giuliano, C; Johnson, LB; Kale-Pradhan, PB | 1 |
| Mehta, J; Pi, J; Trifilio, SM | 1 |
| Beresford, E; Friedland, HD; Huang, X; Lodise, T | 1 |
| Cars, O; Forsberg, P; Giske, CG; Hickman, RA; Lagerbäck, P; Tängdén, T | 1 |
| Eckmann, C | 1 |
| Dan, LA; Lim, RL; Ngu, DY; Ooi, A; Wong, A | 1 |
| Dryden, M; Gonzalez, J; Iaconis, JP; Wilson, D; Zhang, Y | 1 |
| Bae, S; Choi, SH; Chong, YP; Kim, HS; Kim, MC; Kim, MN; Kim, SH; Kim, YS; Lee, SO; Park, SJ; Sung, H; Woo, JH | 1 |
| Chang, Y; Hsieh, PH; Hsu, YH; Hu, CC; Shih, HN; Ueng, SW | 1 |
| Cammarata, S; Farley, B; Gardovskis, J; Lawrence, L; Ling, R; Pullman, J; Quintas, M; Sun, E | 1 |
| Cammarata, S; Cruz-Saldariagga, M; Lawrence, L; Liang, S; McManus, A; O'Riordan, W; Poromanski, I; Quintas, M; Teras, J | 1 |
| Miller, LG | 1 |
| Cobian, J; Hall, B; Miller, J; Wilson, K | 1 |
| Arif, S; Bishawi, M; Maskarinec, SA; Milano, C; Miller, RA; Mourad, A | 1 |
| Engelhardt, M; Gonzalez-Rojas, Y; Gumenchuk, I; Hamed, KA; Ionescu, D; Jones, ME; Keech, R; Kim, C; Ninov, B; Overcash, JS; Saulay, M; Simeonov, S; Smart, JI; Waters, M | 1 |
| Greisen, G; Gupta, M; Jakobsen, JC; Korang, SK; Lausten-Thomsen, U; Nava, C; Safi, S | 1 |
6 review(s) available for aztreonam and vancomycin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antibiotic monitoring in body fluids.
Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Biological Assay; Body Fluids; Cephalosporins; Chloramphenicol; Chromatography, Gas; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Humans; Immunoassay; Monitoring, Physiologic; Penicillins; Rifampin; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Thiamphenicol; Vancomycin | 1985 |
Infectious complications in the immunocompromised host. The antimicrobial armamentarium.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Aminoglycosides; Amphotericin B; Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antiprotozoal Agents; Azoles; Aztreonam; Cephalosporins; Fluoroquinolones; Foscarnet; Ganciclovir; Humans; Imipenem; Immunocompromised Host; Infections; Neoplasms; Pneumonia, Pneumocystis; Vancomycin | 1993 |
Mycotic aneurysm of the descending thoracic aorta caused by Pseudomonas aeruginosa in a solid organ transplant recipient: case report and review.
Topics: Adult; Aneurysm, Infected; Aortic Aneurysm, Thoracic; Aztreonam; Blood Vessel Prosthesis Implantation; Debridement; Drug Therapy, Combination; Humans; Infusions, Parenteral; Male; Organ Transplantation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Secondary Prevention; Treatment Outcome; Vancomycin | 2002 |
Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation.
Topics: Adult; Age Factors; Aged; Anti-Bacterial Agents; Aztreonam; Chicago; Ciprofloxacin; Clostridioides difficile; Enterococcus faecium; Enterocolitis, Pseudomembranous; Female; Graft vs Host Disease; Gram-Positive Bacterial Infections; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Risk Factors; Survival Rate; Transplantation, Homologous; Vancomycin; Vancomycin Resistance | 2013 |
Antibiotic regimens for late-onset neonatal sepsis.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; Aztreonam; Bias; Cefazolin; Clavulanic Acid; Drug Therapy, Combination; Floxacillin; Gentamicins; Humans; Infant, Newborn; Neonatal Sepsis; Randomized Controlled Trials as Topic; Ticarcillin; Vancomycin | 2021 |
26 trial(s) available for aztreonam and vancomycin
| Article | Year |
|---|---|
An open, comparative trial of aztreonam with vancomycin and gentamicin with piperacillin in patients with fulminant hepatic failure.
Topics: Adolescent; Adult; Aztreonam; Drug Therapy, Combination; Female; Gentamicins; Humans; Liver Failure; Male; Middle Aged; Piperacillin; Treatment Outcome; Vancomycin | 1992 |
Enterobacteriaceae and neonatal necrotising enterocolitis.
Topics: Aztreonam; Drug Therapy, Combination; England; Enterobacteriaceae Infections; Enterocolitis, Pseudomembranous; Gentamicins; Humans; Incidence; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Intensive Care Units, Neonatal; Intestine, Large; Vancomycin | 1992 |
Aztreonam plus vancomycin versus gentamicin plus piperacillin as empirical therapy for the treatment of fever in neutropenic patients: a randomised controlled study.
Topics: Adult; Aztreonam; Bacteremia; Drug Therapy, Combination; Fever; Gentamicins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Middle Aged; Neutropenia; Piperacillin; Staphylococcal Infections; Staphylococcus epidermidis; Vancomycin | 1992 |
A randomised prospective comparison of oral ofloxacin and intraperitoneal vancomycin plus aztreonam in the treatment of bacterial peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD).
Topics: Administration, Oral; Aztreonam; Bacterial Infections; Drug Therapy, Combination; Humans; Ofloxacin; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Vancomycin | 1991 |
Comparison of imipenem versus cefuroxime plus tobramycin as empirical therapy for febrile granulocytopenic patients and efficacy of vancomycin and aztreonam in case of failure.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Aztreonam; Cefuroxime; Drug Therapy, Combination; Female; Fever of Unknown Origin; Gram-Positive Bacterial Infections; Humans; Imipenem; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Tobramycin; Treatment Failure; Vancomycin | 1994 |
A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Drug Therapy, Combination; Female; Fever; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Leukocyte Count; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Neoplasms; Neutropenia; Neutrophils; Prospective Studies; Vancomycin | 1996 |
Treatment of pneumonia in mechanically ventilated trauma patients. Results of a prospective trial.
Topics: Aztreonam; Bronchoalveolar Lavage Fluid; Cilastatin; Cross Infection; Drug Therapy, Combination; HLA-DR Antigens; Humans; Imipenem; Pneumonia; Prospective Studies; Respiration, Artificial; Vancomycin; Wounds and Injuries | 1997 |
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.
Topics: Acetamides; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Cross Infection; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; Gram-Positive Bacteria; Hospitalization; Humans; Linezolid; Male; Middle Aged; Monobactams; Oxazolidinones; Pneumonia; Safety; Time Factors; Treatment Outcome; Vancomycin | 2001 |
Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia.
Topics: Acetamides; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Cross Infection; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Linezolid; Male; Middle Aged; Oxazolidinones; Pneumonia, Bacterial; Vancomycin | 2003 |
The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Bacteria; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Random Allocation; Skin Diseases, Bacterial; Tigecycline; Vancomycin | 2005 |
Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
Topics: Anti-Bacterial Agents; Aztreonam; Double-Blind Method; Drug Therapy, Combination; Female; Gram-Positive Cocci; Humans; India; Injections, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Nausea; North America; Skin Diseases, Bacterial; South America; Streptococcus pyogenes; Tigecycline; Treatment Outcome; Vancomycin; Vomiting | 2005 |
Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Aztreonam; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Minocycline; Skin Diseases, Bacterial; Tigecycline; Vancomycin | 2005 |
Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
Topics: Acetamides; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Clinical Trials as Topic; Cost-Benefit Analysis; Delivery of Health Care; Drug Costs; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Linezolid; Male; Methicillin Resistance; Middle Aged; Oxazolidinones; Prospective Studies; Regression Analysis; Skin Diseases, Infectious; Streptococcal Infections; Treatment Outcome; Vancomycin | 2006 |
High concentration and bioactivity of vancomycin and aztreonam eluted from Simplex cement spacers in two-stage revision of infected hip implants: a study of 46 patients at an average follow-up of 107 days.
Topics: Aged; Anti-Bacterial Agents; Arthroplasty, Replacement, Hip; Aztreonam; Bone Cements; Chromatography, High Pressure Liquid; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Indicator Dilution Techniques; Male; Middle Aged; Polymethyl Methacrylate; Prosthesis-Related Infections; Reoperation; Synovial Fluid; Vancomycin | 2006 |
Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Female; Humans; Male; Methicillin Resistance; Middle Aged; Recurrence; Skin Diseases, Infectious; Streptococcus agalactiae; Treatment Outcome; Vancomycin | 2007 |
Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective.
Topics: Anti-Bacterial Agents; Aztreonam; Double-Blind Method; Drug Therapy, Combination; Female; Humans; International Agencies; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Skin Diseases, Bacterial; Tigecycline; Treatment Outcome; Vancomycin | 2008 |
Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin; Young Adult | 2010 |
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Humans; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Treatment Outcome; Vancomycin; Young Adult | 2010 |
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Humans; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Treatment Outcome; Vancomycin; Young Adult | 2010 |
Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Treatment Outcome; Vancomycin | 2010 |
Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Double-Blind Method; Drug Therapy, Combination; Female; Humans; India; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Nausea; Skin Diseases, Bacterial; Taiwan; Tigecycline; Vancomycin; Vomiting | 2011 |
CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Biomarkers; Ceftaroline; Cephalosporins; Drug Administration Schedule; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Injections, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Retrospective Studies; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2012 |
A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Prospective Studies; Skin Diseases, Bacterial; Soft Tissue Infections; Systemic Inflammatory Response Syndrome; Treatment Outcome; Vancomycin; Young Adult | 2016 |
Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aztreonam; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fluoroquinolones; Humans; Middle Aged; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin; Young Adult | 2017 |
A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adult; Aztreonam; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin; Young Adult | 2018 |
Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Double-Blind Method; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2021 |
32 other study(ies) available for aztreonam and vancomycin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Pharmacodynamic effects of antibiotics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time.
Topics: Amdinocillin; Amikacin; Animals; Anti-Bacterial Agents; Aztreonam; Cephalosporins; Daptomycin; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Peptides; Piperacillin; Vancomycin | 1992 |
Cavernous tissue antibiotic levels in penile prosthesis surgery.
Topics: Aztreonam; Bacterial Infections; Gentamicins; Humans; Male; Penile Prosthesis; Penis; Prosthesis-Related Infections; Vancomycin | 1992 |
Aztreonam--vancomycin incompatibility.
Topics: Aztreonam; Chemistry, Pharmaceutical; Drug Incompatibility; Vancomycin | 1990 |
Pharmacokinetics of once daily intra-peritoneal aztreonam and vancomycin in the treatment of CAPD peritonitis.
Topics: Aztreonam; Humans; Injections, Intraperitoneal; Kidney Failure, Chronic; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Vancomycin | 1990 |
[Clinical and pharmacokinetic studies on aztreonam in neonates].
Topics: Ampicillin; Aztreonam; Bacteria; Bacterial Infections; Drug Evaluation; Drug Resistance, Microbial; Humans; Infant, Newborn; Vancomycin | 1990 |
In vitro interactions of carumonam in combination with coumermycin, teicoplanin, flucloxacillin and vancomycin.
Topics: Aminocoumarins; Anti-Bacterial Agents; Aztreonam; Bacteria; Cloxacillin; Coumarins; Drug Therapy, Combination; Enterobacter; Floxacillin; Glycopeptides; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Serratia marcescens; Teicoplanin; Vancomycin | 1987 |
In-vitro antimicrobial activity of enoxacin in combination with eight other antibiotics against Pseudomonas aeruginosa, Enterobacteriaceae and Staphylococcus aureus.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefsulodin; Clindamycin; Drug Combinations; Drug Synergism; Enoxacin; Enterobacteriaceae; Microbial Sensitivity Tests; Moxalactam; Naphthyridines; Oxacillin; Piperacillin; Pseudomonas aeruginosa; Staphylococcus aureus; Vancomycin | 1987 |
Antibiotic pharmacokinetics following fluid resuscitation from traumatic shock.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Disease Models, Animal; Female; Fluid Therapy; Hemodynamics; Male; Metabolic Clearance Rate; Shock, Hemorrhagic; Swine; Vancomycin | 1995 |
Acute hepatitis, interstitial nephritis, and eosinophilia.
Topics: Adult; Aztreonam; Chemical and Drug Induced Liver Injury; Eosinophilia; Female; HIV Infections; Humans; Immunocompromised Host; Nephritis; Vancomycin | 1995 |
Compatibility and stability of aztreonam and vancomycin hydrochloride.
Topics: Anti-Bacterial Agents; Aztreonam; Chemical Precipitation; Chromatography, High Pressure Liquid; Drug Incompatibility; Drug Stability; Humans; Monobactams; Nephelometry and Turbidimetry; Vancomycin | 1995 |
In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi.
Topics: Anti-Bacterial Agents; Aztreonam; Borrelia burgdorferi Group; Drug Resistance, Microbial; Fusidic Acid; Humans; Meropenem; Mezlocillin; Microbial Sensitivity Tests; Monobactams; Penicillins; Ribostamycin; Teicoplanin; Thienamycins; Vancomycin | 2001 |
Pilot study for the development of a new campylobacter selective medium at 37 degrees C using aztreonam.
Topics: Amphotericin B; Anti-Bacterial Agents; Aztreonam; Bacterial Typing Techniques; Campylobacter; Culture Media; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Pilot Projects; Temperature; Vancomycin | 2005 |
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution].
Topics: Aminoglycosides; Ampicillin; Anti-Infective Agents; Aztreonam; Cefixime; Cefozopran; Cefpirome; Cefpodoxime; Ceftizoxime; Cephalosporins; Dibekacin; Drug Resistance, Bacterial; Enterococcus faecalis; Escherichia coli; Gentamicins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Proteus mirabilis; Pseudomonas aeruginosa; Quinolones; Serratia marcescens; Staphylococcus aureus; Thienamycins; Urinary Tract Infections; Vancomycin | 2006 |
Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model.
Topics: Acetamides; Anti-Bacterial Agents; Aztreonam; Ceftazidime; Daptomycin; Drug Synergism; Drug Therapy, Combination; Escherichia coli; Linezolid; Microbial Sensitivity Tests; Oxazolidinones; Vancomycin | 2009 |
Early endpoints for acute bacterial skin and skin structure infections.
Topics: Aztreonam; Biomarkers; Ceftaroline; Cephalosporins; Female; Humans; Male; Skin Diseases, Bacterial; Vancomycin | 2012 |
Panton-Valentine leukocidin is not the primary determinant of outcome for Staphylococcus aureus skin infections: evaluation from the CANVAS studies.
Topics: Age Factors; Aztreonam; Bacterial Toxins; Ceftaroline; Cephalosporins; Electrophoresis, Gel, Pulsed-Field; Exotoxins; Female; Genotype; Humans; Leukocidins; Male; Methicillin-Resistant Staphylococcus aureus; Polymerase Chain Reaction; Staphylococcal Skin Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin | 2012 |
Early response of ceftaroline fosamic in the treatment of soft-tissue infections.
Topics: Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Community-Acquired Infections; Endpoint Determination; Humans; Pneumonia; Randomized Controlled Trials as Topic; Retrospective Studies; Soft Tissue Infections; Time Factors; Treatment Outcome; Vancomycin | 2012 |
Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Costs and Cost Analysis; Drug Therapy, Combination; Economics, Hospital; Formularies, Hospital as Topic; Humans; Length of Stay; Models, Economic; Skin Diseases, Bacterial; Vancomycin | 2013 |
Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Ciprofloxacin; Colistin; Daptomycin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Fosfomycin; In Vitro Techniques; Klebsiella pneumoniae; Lipoglycopeptides; Meropenem; Microbial Sensitivity Tests; Minocycline; Rifampin; Thienamycins; Tigecycline; Vancomycin | 2014 |
[Efficacy of ceftaroline in treating complicated skin and soft tissue infections].
Topics: Aztreonam; Ceftaroline; Cephalosporins; Drug Therapy, Combination; Humans; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Soft Tissue Infections; Vancomycin | 2014 |
Detection of antibiotic resistance in probiotics of dietary supplements.
Topics: Aztreonam; Bacteria; Ciprofloxacin; Dietary Supplements; Drug Resistance, Bacterial; Food Microbiology; Gentamicins; Lactobacillus; Pilot Projects; Probiotics; Streptomycin; Vancomycin | 2015 |
In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Aztreonam; Bacteremia; Ceftazidime; Colistin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Retrospective Studies; Rifampin; Teicoplanin; Thienamycins; Vancomycin | 2016 |
Vancomycin and Ceftazidime in Bone Cement as a Potentially Effective Treatment for Knee Periprosthetic Joint Infection.
Topics: Aged; Anti-Bacterial Agents; Aztreonam; Bone Cements; Ceftazidime; Chronic Disease; Female; Humans; Imipenem; Knee Prosthesis; Male; Middle Aged; Prosthesis-Related Infections; Teicoplanin; Treatment Outcome; Vancomycin | 2017 |
Another New Antibiotic for Skin Infections and Why Infectious Disease Specialists Are Hypocrites.
Topics: Anti-Bacterial Agents; Aztreonam; Double-Blind Method; Fluoroquinolones; Humans; Infections; Specialization; Vancomycin | 2019 |
Impact of SEP-1 on broad-spectrum combination antibiotic therapy in the emergency department.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Centers for Medicare and Medicaid Services, U.S.; Early Diagnosis; Early Medical Intervention; Emergency Service, Hospital; Female; Guideline Adherence; Hospital Mortality; Hospitalization; Humans; Male; Medical Overuse; Meropenem; Middle Aged; Patient Care Bundles; Piperacillin, Tazobactam Drug Combination; Reimbursement Mechanisms; Retrospective Studies; Sepsis; Shock, Septic; Soft Tissue Infections; Time-to-Treatment; United States; Urinary Tract Infections; Vancomycin | 2020 |
Surgical infection prophylaxis prior to left ventricular assist device implantation: A survey of clinical practice.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Aztreonam; Cephalosporins; Cross-Sectional Studies; Drug Therapy, Combination; Fluconazole; Heart-Assist Devices; Humans; Levofloxacin; Prosthesis Implantation; Prosthesis-Related Infections; Rifampin; Surgical Wound Infection; Surveys and Questionnaires; Vancomycin | 2020 |